| # | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
|---|
Poster Presentation on VENTURE Study Results Evaluating Impact of VK2735 on Prediabetes and Cardiometabolic StatusAdditional Po...
Canaccord Genuity analyst Edward Nash initiates coverage on Viking Therapeutics (NASDAQ:VKTX) with a Buy rating and announce...
JP Morgan analyst Hardik Parikh maintains Viking Therapeutics (NASDAQ:VKTX) with a Overweight and lowers the price target fr...
Viking Therapeutics shares are rising Thursday. The clinical-stage biopharmaceutical company reported third-quarter earnings an...
Morgan Stanley analyst Michael Ulz maintains Viking Therapeutics (NASDAQ:VKTX) with a Overweight and raises the price target...
Viking Therapeutics (NASDAQ:VKTX) reported quarterly losses of $(0.81) per share which missed the analyst consensus estimate of...